Velázquez-Hernández María-Elena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Velázquez-Hernández María-Elena has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alain Raimundo Rodríguez Orozco
Facultad de Ciencias Médicas y Biológicas “Dr. Ignacio Chávez”, Universidad Michoacana de San Nicolás de Hidalgo, Morelia 58020, Mexico
2 shared publications - Manuel Garcia-Perez
Facultad de Químico-Farmacobiología, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico
2 shared publications - Claudia Cervantes‐Durán
Escuela Nacional de Estudios Superiores Unidad Morelia, UNAM. Morelia, Michoacán, México
1 shared publication - Isis Beatriz Bermudez Camps
Universidad Autónoma del Estado de Hidalgo
1 shared publication - Ivette Reyes Hernández
Universidad Autónoma del Estado de Hidalgo, México
1 shared publication - Josue Valentin-Escalera
Neurosciences Axis Centre de recherche du CHU de Québec Université Laval Quebec City Quebec Canada
1 shared publication
Latest Publications
- Open Access
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Adverse events and potential herb-drug interactions of plants used for psoriasis: A systematic review
Context: Medicinal plants have been widely used for psoriasis management for centuries. However, their safety profiles remain insufficiently documented. Aims: To systematically evaluate adverse events (AEs) and potential pharmacokinetic interactions of antipsoriatic herbal treatments. Methods: A PRISMA-compliant review was conducted using PubMed, Cochrane, Google Scholar, Web of Science, and Scopus databases (January 2015-December 2022). Clinical trials, case reports, and ethnomedicinal studies reporting AEs of single plant antipsoriatic preparations were included. CONSORT criteria for herbal medicines were applied to assess study quality. Results: Eleven studies covering nine herbal treatments were included. While most of reported AEs were mild, severe cases involving Indigo naturalis, Psoralea corylifolia, and Ranunculus arvensis were documented. Several herbal metabolites (indirubin, psoralen, curcumin, triptolide) showed potential pharmacokinetic interactions with conventional drugs. Conclusions: While generally well tolerated, antipsoriatic herbal therapies can induce mild to severe AEs and may alter drug metabolism. Long-term, high-quality randomized trials are needed to establish their safety profile.
- 1 March 2026
- Published by Garval Editorial Ltda. in Journal of Pharmacy & Pharmacognosy Research
- Vol. 14 (2)
Open AccessAdverse events and potential herb-drug interactions of plants used for psoriasis: A systematic review
Context: Medicinal plants have been widely used for psoriasis management for centuries. However, their safety profiles remain insufficiently documented. Aims: To systematically evaluate adverse events (AEs) and potential pharmacokinetic interactions of antipsoriatic herbal treatments. Methods: A PRISMA-compliant review was conducted using PubMed, Cochrane, Google Scholar, Web of Science, and Scopus databases (January 2015-December 2022). Clinical trials, case reports, and ethnomedicinal studies reporting AEs of single plant antipsoriatic preparations were included. CONSORT criteria for herbal medicines were applied to assess study quality. Results: Eleven studies covering nine herbal treatments were included. While most of reported AEs were mild, severe cases involving Indigo naturalis, Psoralea corylifolia, and Ranunculus arvensis were documented. Several herbal metabolites (indirubin, psoralen, curcumin, triptolide) showed potential pharmacokinetic interactions with conventional drugs. Conclusions: While generally well tolerated, antipsoriatic herbal therapies can induce mild to severe AEs and may alter drug metabolism. Long-term, high-quality randomized trials are needed to establish their safety profile.
- 14 March 2020
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 312 (9) , 611-627
Small molecules under development for psoriasis: on the road to the individualized therapies
Psoriasis is an incurable cutaneous illness characterized by the presence of well-delimited reddish plaques and silvery-white dry scales. So far, there is a limited understanding of its pathogenesis, though recent discoveries on the immunological, genetic and molecular aspects of this disease have significantly contributed to the identification of new targets and the development of novel drugs. Despite these advances, many patients are still dissatisfied, so to improve patient satisfaction, reliability, and clinical outcomes, the individualization of the treatments for this disease becomes a necessity. This review summarizes recent findings related to psoriasis pathogenesis and describes new small molecules and targets recently identified as promising for treatments. Additionally, the current status, challenges and the future directions for achieving individualized therapy for this disease and the need for more collaborative studies are discussed. The individualization of treatments for psoriasis, rather than a goal, is analyzed as a process where a dynamic integration between the needs and characteristics of the patients, the pharmacological progress, and the clinical decisions takes place.
- 14 March 2020
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 312 (9) , 611-627
Small molecules under development for psoriasis: on the road to the individualized therapies
Psoriasis is an incurable cutaneous illness characterized by the presence of well-delimited reddish plaques and silvery-white dry scales. So far, there is a limited understanding of its pathogenesis, though recent discoveries on the immunological, genetic and molecular aspects of this disease have significantly contributed to the identification of new targets and the development of novel drugs. Despite these advances, many patients are still dissatisfied, so to improve patient satisfaction, reliability, and clinical outcomes, the individualization of the treatments for this disease becomes a necessity. This review summarizes recent findings related to psoriasis pathogenesis and describes new small molecules and targets recently identified as promising for treatments. Additionally, the current status, challenges and the future directions for achieving individualized therapy for this disease and the need for more collaborative studies are discussed. The individualization of treatments for psoriasis, rather than a goal, is analyzed as a process where a dynamic integration between the needs and characteristics of the patients, the pharmacological progress, and the clinical decisions takes place.